CPS
All Resources
Browse all available resources on the CDx Digital Education Portal by media type, cancer indication, and skill level.
PD-L1 IHC 22C3 pharmDx Interpretation Training Program for Esophageal Squamous Cell Carcinoma (ESCC)
PD-L1 IHC 22C3 pharmDx Interpretation Training Program for Head and Neck Squamous Cell Carcinoma (HNSCC)
PD-L1 IHC 22C3 pharmDx Interpretation Training Program for Non-Small Cell Lung Cancer (NSCLC)
PD-L1 IHC 22C3 pharmDx Interpretation Training Program for Triple-Negative Breast Cancer (TNBC)
PD-L1 IHC 22C3 pharmDx Interpretation Manual for Esophageal Squamous Cell Carcinoma (ESCC)
PD-L1 IHC 22C3 pharmDx Interpretation Manual for Head and Neck Squamous Cell Carcinoma (HNSCC)
PD-L1 IHC 22C3 pharmDx Quick Scoring Guide for Head and Neck Squamous Cell Carcinoma (HNSCC)
Confidence in Evaluating Combined Positive Score: How a Systematic Approach Can Simplify PD-L1 Scoring with CPS
Scoring of Triple-Negative Breast Cancer (TNBC): Example Cases from PD-L1 IHC 22C3 pharmDx Atlas of Stain
Assessing PD-L1 Combined Positive Score (CPS) in Various Tumor Types with Distinct Morphological Characteristics
Implementation of PD-L1 Testing in the New Era of an Everchanging Immuno-oncology Landscape
The Rationale Behind the Scoring Systems for PD-L1 IHC to Determine Patients Eligible for KEYTRUDA (pembrolizumab)
D72588_02